Nuclein, LLC, an Austin, Texas-based medical device company, closed a $14m Series B funding round.
The round was led by Trinity Private Equity Group, a Southlake, Texas-based private equity firm.
The company intends to use the funds to to commercialize its novel, hand-held PCR platform designed as a disposable, all-in-one, self-test for infectious disease diagnosis.
Led by Alan Blake, CEO and co-founder, and Dr. Richard Crockett, president and co-founder, Nuclein provides a device that runs real-time PCR, does not require technical expertise to operate, and delivers battery-powered, sample-to-answer results from saliva in under one hour, without the need to mail in a sample. While the Nuclein technology platform has been designed to detect any infectious disease target, the company is currently focusing on COVID-19 to assist with the ongoing pandemic.
Source: FinSME
